24/7 Market News Snapshot 10 June, 2025 – X4 Pharmaceuticals, Inc. Common Stock (NASDAQ:XFOR)

June 10, 2025

DENVER, Colo., 10 June, 2025 (www.247marketnews.com) – (NASDAQ:XFOR) are discussed in this article.
X4 Pharmaceuticals, Inc. is witnessing a strong uptick in early trading, with shares rising 12.99% to $4.678, up from the previous close of $4.140. The increase is supported by a substantial trading volume of 849.20K shares, highlighting robust investor interest. This momentum suggests a favorable market sentiment, likely influenced by recent positive developments concerning the company.

In a significant announcement, X4 Pharmaceuticals has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its oral CXCR4 antagonist, mavorixafor, aimed at treating chronic neutropenia (CN). This designation underscores the FDA’s recognition of the urgent unmet medical needs in the chronic neutropenia patient population. Mavorixafor is currently undergoing evaluation in the pivotal Phase 3 clinical trial, known as 4WARD, which is designed to assess its efficacy, safety, and tolerability in patients with specified primary chronic neutropenia conditions. X4 expects to complete full enrollment in this trial by the third or fourth quarter of this year, anticipating the release of top-line data by late 2026.

Dr. Christophe Arbet-Engels, Chief Medical Officer of X4 Pharmaceuticals, remarked on the importance of this milestone, emphasizing the potential of mavorixafor to significantly improve the quality of life for patients afflicted with this challenging condition. Currently, the only FDA-approved treatment for chronic neutropenia involves the administration of injectable human recombinant granulocyte-colony stimulating factor (G-CSF), which comes with a range of side effects that can complicate patient care.

The Fast Track designation is expected to enhance communication between X4 Pharmaceuticals and regulatory authorities, potentially accelerating the approval process for mavorixafor. As the company commits to advancing innovative solutions for rare immune system disorders, it aims to transition research breakthroughs into effective treatments, offering hope to patients around the globe.

Related news for (XFOR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.